At Last: Acadia Submits NDA, Makes Davis Permanent CEO
This article was originally published in Scrip
Executive Summary
Following delay after delay, Acadia Pharmaceuticals finally submitted a new drug application (NDA) to the US FDA seeking approval for Nuplazid (pimavanserin) nearly three years after the company reported positive Phase III results in the treatment of Parkinson's disease psychosis (PDP).